X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (13222) 13222
Newspaper Article (3191) 3191
Publication (1805) 1805
Book Review (284) 284
Newsletter (205) 205
Trade Publication Article (201) 201
Magazine Article (142) 142
Book Chapter (114) 114
Web Resource (87) 87
Book / eBook (66) 66
Conference Proceeding (38) 38
Dissertation (11) 11
Government Document (4) 4
Reference (3) 3
Data Set (2) 2
Report (2) 2
Paper (1) 1
Transcript (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (7752) 7752
immunotherapy (7559) 7559
immune system (6635) 6635
cancer (6378) 6378
oncology (5598) 5598
humans (5479) 5479
tumors (4413) 4413
immunology (3991) 3991
cancer therapies (3269) 3269
animals (3198) 3198
lymphocytes (3089) 3089
melanoma (3083) 3083
immune response (2707) 2707
patients (2558) 2558
immune checkpoint (2510) 2510
metastasis (2478) 2478
chemotherapy (2463) 2463
clinical trials (2199) 2199
research (2165) 2165
apoptosis (2133) 2133
antigens (2087) 2087
care and treatment (2084) 2084
t cells (2042) 2042
medical research (2028) 2028
lymphocytes t (1888) 1888
proteins (1705) 1705
lung cancer (1631) 1631
mice (1550) 1550
dendritic cells (1513) 1513
female (1501) 1501
health aspects (1469) 1469
review (1452) 1452
gene expression (1447) 1447
nivolumab (1415) 1415
expression (1404) 1404
cell biology (1374) 1374
analysis (1362) 1362
article (1346) 1346
cytokines (1331) 1331
cytotoxicity (1310) 1310
inflammation (1281) 1281
mutation (1230) 1230
male (1207) 1207
pharmaceutical industry (1129) 1129
t-cells (1120) 1120
medicine (1112) 1112
ipilimumab (1087) 1087
metastases (1078) 1078
studies (1077) 1077
immune checkpoint inhibitors (1053) 1053
therapy (1040) 1040
biomarkers (1032) 1032
kinases (1007) 1007
ligands (998) 998
genetic aspects (982) 982
regulatory t-cells (978) 978
survival (974) 974
signal transduction (968) 968
medical prognosis (967) 967
pd-1 (960) 960
vaccines (945) 945
activation (940) 940
neoplasms - immunology (938) 938
pembrolizumab (936) 936
cell death (919) 919
drug therapy (919) 919
development and progression (906) 906
immunotherapy - methods (900) 900
immunity (899) 899
multidisciplinary sciences (885) 885
research article (885) 885
pd-1 protein (858) 858
tumor microenvironment (847) 847
biochemistry & molecular biology (831) 831
medicine, research & experimental (827) 827
t cell receptors (827) 827
pd-l1 (825) 825
breast cancer (812) 812
medicine & public health (795) 795
open-label (788) 788
middle aged (772) 772
pd-l1 protein (765) 765
immunoglobulins (755) 755
prognosis (744) 744
neoplasms. tumors. oncology. including cancer and carcinogens (723) 723
hematology (720) 720
biology (715) 715
aged (713) 713
deoxyribonucleic acid--dna (699) 699
science (698) 698
lymphomas (690) 690
physiological aspects (688) 688
antibodies (679) 679
blockade (678) 678
metastatic melanoma (676) 676
macrophages (658) 658
neoplasms - therapy (656) 656
usage (632) 632
cells (626) 626
immune checkpoint inhibitor (618) 618
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (39) 39
Collection Dvlpm't (Acquisitions) - Closed Orders (8) 8
Collection Dvlpm't (Acquisitions) - Vendor file (5) 5
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (5) 5
Trinity College (John W Graham) - Stacks (4) 4
UofT at Mississauga - Stacks (4) 4
Humber River Regional Hospital - Finch Stacks (3) 3
Humber River Regional Hospital - Church Stacks (2) 2
Online Resources - Online (2) 2
St. Michael's Hospital - Stacks (2) 2
UofT at Scarborough - Stacks (2) 2
Women's College Hospital - Stacks (2) 2
Credit Valley Hospital - Stacks (1) 1
Earth Sciences (Noranda) - Circulation Desk (1) 1
Earth Sciences (Noranda) - Oversize (1) 1
Earth Sciences (Noranda) - Stacks (1) 1
Gerstein Science - Circulation Desk (1) 1
Gerstein Science - Reserve desk (1) 1
Knox College (Caven) - Stacks (1) 1
Mt Sinai Hospital - Pathology (1) 1
New College (Ivey) - Stacks (1) 1
Providence Healthcare - Reference (1) 1
Providence Healthcare - Stacks (1) 1
Scarborough Hospital - General (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
St. Michael's College (John M. Kelly) - Circulation Desk (1) 1
Toronto East General Hospital - Online (1) 1
Trillium Health Centre - Reserve desk (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Mississauga - Circulation Desk (1) 1
Victoria University E.J. Pratt - Circulation Desk (1) 1
Victoria University E.J. Pratt - Oversize (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (16932) 16932
German (100) 100
French (60) 60
Japanese (29) 29
Chinese (27) 27
Spanish (14) 14
Korean (7) 7
Russian (5) 5
Polish (3) 3
Turkish (3) 3
Portuguese (2) 2
Czech (1) 1
Dutch (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Treatment Reviews, ISSN 0305-7372, 2016, Volume 44, pp. 51 - 60
Highlights • Role of immune checkpoint inhibition in the management of key malignancies. • Description of rates of immune-related adverse events and timing of... 
Hematology, Oncology and Palliative Medicine | Pembrolizumab | Immune-related adverse events | Renal cancer | Ipilimumab | Nivolumab | Lung cancer | Melanoma | Immune-checkpoint inhibitors | OPEN-LABEL | SINGLE-ARM | ANTI-CTLA-4 ANTIBODY | METASTATIC MELANOMA | ONCOLOGY | ADVANCED MELANOMA | LONG-TERM SAFETY | MALIGNANT MESOTHELIOMA | ENTERIC NEUROPATHY | ADVERSE EVENTS | IPILIMUMAB RETREATMENT | Lung Neoplasms - drug therapy | Skin Neoplasms - drug therapy | Humans | Immunosuppressive Agents - therapeutic use | Antibodies, Monoclonal - adverse effects | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Adrenal Cortex Hormones - therapeutic use | Diarrhea - chemically induced | Infliximab - therapeutic use | Drug Eruptions - drug therapy | Antineoplastic Agents - adverse effects | Colitis - chemically induced | Antilymphocyte Serum - therapeutic use | Colitis - drug therapy | Carcinoma, Renal Cell - drug therapy | Chemical and Drug Induced Liver Injury - etiology | Pituitary Diseases - chemically induced | Pituitary Diseases - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Drug Eruptions - etiology | Neoplasms - drug therapy | Cyclosporine - therapeutic use | Tacrolimus - therapeutic use | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - therapeutic use | Melanoma - drug therapy | Chemical and Drug Induced Liver Injury - drug therapy | Diarrhea - drug therapy | CTLA-4 Antigen - antagonists & inhibitors | Kidney Neoplasms - drug therapy | Thyroiditis - drug therapy | Thyroiditis - chemically induced | Index Medicus
Journal Article
Journal of Cell Biology, ISSN 0021-9525, 03/2019, Volume 218, Issue 3, pp. 740 - 741
Immunotherapy, harnessing the immune system to combat cancers, has yielded promising results in patient care. Monoclonal antibodies that block the “immune... 
SIGNALS | CELL BIOLOGY | CTLA-4 protein | Immune checkpoint | PD-1 protein | Immunotherapy | PD-L1 protein | Blocking antibodies | Monoclonal antibodies | Blocking | Tumors | Immune system | Discussion
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2019, Volume 78, Issue 6, pp. e58 - e58
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 04/2018, Volume 71, Issue 16, pp. 1755 - 1764
Journal Article
Cancer, ISSN 0008-543X, 06/2017, Volume 123, Issue 11, pp. 1904 - 1911
Immune checkpoint inhibitors, including those targeting the programmed cell death 1/programmed cell death ligand 1 and cytotoxic T lymphocyte antigen 4... 
pembrolizumab | autoimmune | nivolumab | elderly | ipilimumab | pediatrics | pregnancy | transplant | organ dysfunction | ALLOGRAFT-REJECTION | PERFORMANCE STATUS | PD-1 BLOCKADE | OPEN-LABEL | CELL LUNG-CANCER | IPILIMUMAB THERAPY | ONCOLOGY | ADVANCED MELANOMA | BRAIN METASTASES | AUTOIMMUNE-DISEASE | T-CELLS | Lung Neoplasms - drug therapy | Melanoma - complications | Age Factors | Humans | Immunosuppressive Agents - therapeutic use | Ipilimumab | Antibodies, Monoclonal - therapeutic use | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Hepatitis C, Chronic - complications | Transplant Recipients | Neoplasms - complications | Brain Neoplasms - secondary | Squamous Cell Carcinoma of Head and Neck | Pregnancy Complications, Neoplastic - drug therapy | Female | Carcinoma, Renal Cell - drug therapy | Kidney Neoplasms - complications | Graft Rejection - prevention & control | Autoimmune Diseases - complications | Head and Neck Neoplasms - drug therapy | Brain Neoplasms - drug therapy | Lung Neoplasms - complications | Neoplasms - drug therapy | Pregnancy | Carcinoma, Non-Small-Cell Lung - complications | B7-H1 Antigen - antagonists & inhibitors | Carcinoma, Squamous Cell - drug therapy | Hepatitis B, Chronic - complications | Carcinoma, Squamous Cell - complications | Melanoma - drug therapy | Nivolumab | HIV Infections - complications | Head and Neck Neoplasms - complications | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Renal Cell - complications | Immunocompromised Host | CTLA-4 Antigen - antagonists & inhibitors | Kidney Neoplasms - drug therapy | Virus diseases | Care and treatment | Dosage and administration | Research | Cell death | Immunosuppressive agents | Medical research | Brain | Populations | Toxicity | Decision making | Mortality | Disorders | Clinical trials | Cytotoxicity | Lymphocytes T | Metastasis | Patients | Regulatory approval | Metastases | Inhibitors | Immune checkpoint | Aggregates | Lymphocytes | Safety | Autoimmune diseases | Cancer | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Hematology and Oncology, ISSN 1756-8722, 05/2017, Volume 10, Issue 1, pp. 103 - 16
Inhibitory molecules such as PD-1, CTLA-4, LAG-3, or TIM-3 play a role to keep a balance in immune function. However, many cancers exploit such molecules to... 
PD-L1 | PD-L2 | Hematologic malignancies | CTLA-4 | Immune checkpoint | PD-1 | MULTIPLE-MYELOMA | PD-1 BLOCKADE | BRENTUXIMAB VEDOTIN | ACUTE MYELOID-LEUKEMIA | CD8(+) T-CELLS | B-CELL LYMPHOMA | ONCOLOGY | CLASSICAL HODGKIN LYMPHOMA | DEATH LIGAND 1 | HEMATOLOGY | NF-KAPPA-B | Tumor Escape - drug effects | B7-H1 Antigen - physiology | Humans | Hepatitis A Virus Cellular Receptor 2 - physiology | Neoplasm Proteins - antagonists & inhibitors | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Clinical Trials as Topic | Antigens, CD - drug effects | Programmed Cell Death 1 Receptor - physiology | Molecular Targeted Therapy | Antigen-Presenting Cells - immunology | Biomarkers, Tumor | Patient Selection | Antineoplastic Agents, Immunological - adverse effects | Hepatitis A Virus Cellular Receptor 2 - antagonists & inhibitors | B7-H1 Antigen - antagonists & inhibitors | Multicenter Studies as Topic | Antineoplastic Agents, Immunological - therapeutic use | Lymphocyte Activation - drug effects | Hematologic Neoplasms - drug therapy | Antigens, CD - physiology | CTLA-4 Antigen - antagonists & inhibitors | CTLA-4 Antigen - physiology | PD-1 protein | Lung cancer | Clinical trials | Recovery of function | Cytotoxicity | Biology | CD223 antigen | Myeloma | Myelodysplastic syndrome | Proteins | CTLA-4 protein | Immunology | Lymphocytes | Immunotherapy | Janus kinase 2 | Antigens | Immunoglobulins | Immune response | Hematology | Myeloid leukemia | Melanoma | Immunosurveillance | T cell receptors | Lymphoma | PD-L1 protein | Biomarkers | Ligands | Lymphomas | Acute myeloid leukemia | Binding sites | Hodgkin's disease | Apoptosis
Journal Article
Current Opinion in Neurology, ISSN 1350-7540, 11/2016, Volume 29, Issue 6, pp. 806 - 812
Purpose of review In recent years, advances in the understanding of the regulatory mechanisms of the immune system has led to the development of new approaches... 
Neurologic side-effects | Pembrolizumab | Immune checkpoint inhibitors | Ipilimumab | Nivolumab | ACTIVATION | nivolumab | ANTIGEN-4 MONOCLONAL-ANTIBODY | neurologic side-effects | immune checkpoint inhibitors | STAGE-III | NEUROSCIENCES | CLINICAL NEUROLOGY | pembrolizumab | METASTATIC MELANOMA | IPILIMUMAB THERAPY | TOXICITIES | NEUROPATHY | AUTOIMMUNITY | ipilimumab | ASSOCIATION
Journal Article